Madrigal Pharmaceuticals (MDGL) EBITDA (2019 - 2025)
Historic EBITDA for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to -$114.0 million.
- Madrigal Pharmaceuticals' EBITDA rose 200.25% to -$114.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$307.5 million, marking a year-over-year increase of 4389.53%. This contributed to the annual value of -$497.9 million for FY2024, which is 3084.89% down from last year.
- According to the latest figures from Q3 2025, Madrigal Pharmaceuticals' EBITDA is -$114.0 million, which was up 200.25% from -$47.2 million recorded in Q2 2025.
- In the past 5 years, Madrigal Pharmaceuticals' EBITDA ranged from a high of -$47.2 million in Q2 2025 and a low of -$162.5 million during Q2 2024
- Its 5-year average for EBITDA is -$87.1 million, with a median of -$79.3 million in 2025.
- Per our database at Business Quant, Madrigal Pharmaceuticals' EBITDA crashed by 9408.32% in 2024 and then soared by 7095.92% in 2025.
- Quarter analysis of 5 years shows Madrigal Pharmaceuticals' EBITDA stood at -$64.6 million in 2021, then tumbled by 32.04% to -$85.3 million in 2022, then plummeted by 37.37% to -$117.2 million in 2023, then skyrocketed by 42.82% to -$67.0 million in 2024, then crashed by 70.12% to -$114.0 million in 2025.
- Its last three reported values are -$114.0 million in Q3 2025, -$47.2 million for Q2 2025, and -$79.3 million during Q1 2025.